Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1643 1644
This examiner grants 53% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17997137 | CCR7 ANTIBODY DRUG CONJUGATES FOR TREATING CANCER | Non-Final OA | Novartis AG |
| 17595671 | COMBINATION THERAPY | Non-Final OA | Dana-Farber Cancer Institute, Inc. |
| 18467137 | THERAPEUTIC BINDING MOLECULES | Final Rejection | MedImmune Limited |
| 17598780 | NUCLEAR-DERIVED EXOSOMES AND METHODS OF USE THEREOF | Final Rejection | Board of Regents, The University of Texas System |
| 18016864 | COMBINATION OF ANTI-HER2 ANTIBODY-DRUG CONJUGATE WITH HER DIMERIZATION INHIBITOR | Non-Final OA | DAIICHI SANKYO COMPANY, LIMITED |
| 17312084 | COMBINATION OF ANTIBODY-DRUG CONJUGATE WITH PARP INHIBITOR | Final Rejection | DAIICHI SANKYO COMPANY, LIMITED |
| 17752892 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROSTATE CANCER | Final Rejection | Janssen Biotech, Inc. |
| 17674397 | Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors | Final Rejection | Janssen Biotech, Inc. |
| 18337631 | ANTIBODY CONJUGATE AND METHOD FOR ENHANCING IMMUNE EFFECT FUNCTION OF ANTIBODY MOLECULE | Non-Final OA | JIANGNAN UNIVERSITY |
| 17242559 | Immune CB1 Activation for Obesity Therapy | Non-Final OA | University of South Carolina |
| 17438993 | ANTIGEN-BINDING MOLECULE CONTAINING ANTIGEN-BINDING DOMAIN OF WHICH BINDING ACTIVITY TO ANTIGEN IS CHANGED DEPENDING ON MTA, AND LIBRARY FOR OBTAINING SAID ANTIGEN-BINDING DOMAIN | Non-Final OA | Chugai Seiyaku Kabushiki Kaisha |
| 17282589 | Anti-FGFR2 Antibody Formulations | Non-Final OA | Five Prime Therapeutics, Inc. |
| 18263091 | ANTIBODY-DRUG CONJUGATE AND MEDICAL USE THEREOF | Non-Final OA | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. |
| 18257436 | ROR1-SPECIFIC VARIANT ANTIGEN BINDING MOLECULES | Non-Final OA | ALMAC DISCOVERY LIMITED |
| 18253940 | ANTI-CLIC1 PROTEIN ANTIBODIES AND THE DIAGNOSTIC AND THERAPEUTIC USES THEREOF | Non-Final OA | Universita' Degli Studi di Milano |
| 17613006 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | Non-Final OA | LES LABORATOIRES SERVIER |
| 18012723 | CONJUGATE OF A SINGLE DOMAIN ANTIBODY, A SAPONIN AND AN EFFECTOR MOLECULE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, THERAPEUTIC USE OF SAID PHARMACEUTICAL COMPOSITION | Non-Final OA | SAPREME TECHNOLOGIES B.V. |
| 18012741 | COMBINATION COMPRISING AN ADC OR AN AOC COMPRISING A VHH, AND A SAPONIN OR A LIGAND-SAPONIN CONJUGATE | Final Rejection | SAPREME TECHNOLOGIES B.V. |
| 18155650 | BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | Final Rejection | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. |
| 17998772 | ANTIBODY DRUG CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | Non-Final OA | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. |
| 18016275 | ANTIBODY DRUG CONJUGATE INTERMEDIATE CONTAINING SN38 AND ITS PREPARATION METHOD | Non-Final OA | MABPLEX INTERNATIONAL CO., LTD. |
| 17823025 | ANTI-FENTANYL ANTIBODIES | Non-Final OA | Hepione Therapeutics Inc. |
| 17907941 | TUMOR IMMUNE ENHANCER, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Non-Final OA | WUXI PLB THERAPEUTICS TECHNOLOGY LIMITED. CO |
| 17279327 | CULTURE OF TUMOR INFILTRATING LYMPHOCYTES FROM TUMOR DIGEST | Non-Final OA | Amod SARNAIK |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy